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•A PubMed search was performed, using the keywords:
insulinoma”, “neuroendocrine pancreatic tumors”, “islet cell
arcinoma”, “malignant insulinoma”, and limited to reports on
uman adults and English-language publications (except for
rench-language guidelines), including case reports.
Due to its rarity, there is currently no dedicated guidelines for
reatment strategy and follow-up specific to malignant insuli-
oma [1]. Management is generally assimilated to that for
ell-differentiated functional pancreatic endocrine tumors [2].
he hypoglycaemia-related morbidity and mortality of malig-
ant insulinoma, however, requires strategic adaptation. The
DOIs of original articles:http://dx.doi.org/10.1016/j.ando.2013.05.009,
ttp://dx.doi.org/10.1016/j.ando.2013.05.005,
ttp://dx.doi.org/10.1016/j.ando.2013.05.006,
ttp://dx.doi.org/10.1016/j.ando.2013.05.008,
ttp://dx.doi.org/10.1016/j.ando.2013.05.004,
ttp://dx.doi.org/10.1016/j.ando.2013.05.002,
ttp://dx.doi.org/10.1016/j.ando.2013.05.003
 Hypoglycemia in non-diabetic patient.
♦ L’hypoglycémie chez le patient non diabétique.
∗ Corresponding author.
E-mail address: christine.docao@chru-lille.fr (C. Do Cao).
c
o
l
g
1
p
I
i
003-4266/$ – see front matter © 2013 Elsevier Masson SAS. All rights reserved.
ttp://dx.doi.org/10.1016/j.ando.2013.07.001uidelines presented here are therefore based on published data
elating to:
 symptomatic control of benign and malignant insulinoma;
 antitumoral control of malignant insulinoma;
 symptomatic and antitumoral control of functional and/or
non-functional pancreatic neuroendocrine tumors (NETs).
The European and American treatment guidelines for pan-
reatic NETs have been taken into account [2,3]. A consensus
f French experts was sought for each treatment proposal. The
ow level of evidence of the publications (level 4) precluded
uidelines above grade C (expert opinion).
.  Deﬁnition,  epidemiology
Insulinoma malignancy is confirmed by presence of extra-
ancreatic locoregional, lymph-node or remote extension.
nsulinoma is malignant in 4–14% of cases [4–10].
Two other definitions, based on pathology results, are used
n the current guidelines:
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 insulinoma of uncertain prognosis (size greater than 2 cm or
grade 2 based on the 2010 WHO classification, or vascular
and/or perineural invasion or necrosis);
 benign insulinoma if none of the above.
Very few prognostic series dedicated to insulinoma have
een published yet. Therefore it seems important to keep the
haracterisation as broad and precise as possible, awaiting data
rom large well-characterized cohort of patients with prolonged
ollow-up to refine diagnostic and prognostic factors. Param-
ters, listed above, were selected according to retrospective
tudies of pancreatic NETs or insulinomas [8,11–13].
.  Characterisation
.1.  Pathology
Insulinomas are categorised according to the 2010 WHO,
007 ENETS and 2010 UICC-pTNM classifications of NETs.
he vast majority present as well-differentiated tumors and
oorly differentiated insulinoma seem not having been reported
n the literature. Even so, given the prognostic importance of
he differentiation status and a few reports of unusual aggres-
ive clinical presentations of malignant insulinoma that mimics
oorly differentiated carcinoma, the prognostic importance and
herapeutic impact of such classification is to be underlined
14–16].
The ENETS and UICC-pTNM classifications require the
athologist to specify the size and number of resected nodes,
ow many of these are metastatic, extrapancreatic extension and
egree of invasion.
Insulinoma is usually discovered as a localised tumor, with
ecovery demonstrated by the disappearance of hypoglycaemic
ymptoms in more than 90% of cases. In such setting lymph-
ode status is usually unknown.
The median size of malignant insulinoma at diagnosis ranges
rom 2.3 to 6.2 cm [4,8,17,18]. There is no absolute threshold of
ize corresponding to malignancy: in three reports, 40–80% of
etastatic insulinomas measured less than 2 cm [5,7,17].
Certain criteria of the 2004 WHO classification no longer
ppear in the new 2010 WHO classification like necrosis and
ascular or perineural invasion; we nevertheless consider them
s noteworthy while prognostic series dedicated to insulinoma
re lacking. The quality of resection (R status) and the number
f tumors are also worth being recorded.
.2.  Anatomic  locationMost (> 99%) malignant insulinomas are pancreatic. There
s no clear pattern of intrapancreatic location, although cer-
ain authors consider caudal locations to be the most frequent
5,7,17]. When there is no identifiable pancreatic primary lesion,
n extrapancreatic location should be considered as an alterna-
ive to the presence of a small insulinoma [19].
f
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.3.  Clinical  presentation
Onset of malignant insulinoma is typically in the 5th or 6th
ecade of life. No sex predominance has been demonstrated.
alignant insulinoma is by definition functional, characterised
y clinical hypoglycaemic manifestations together with low
lasma glucose and inadequate insulin secretion, which are
elieved by intake of sugar. The frequency and severity of symp-
oms and their impact on quality of life, the level of anxiety or
epression of the patient and his or her close relations should be
ssessed. During hospitalisation, the psychological impact of the
atient’s symptomatology on the health-care team should also be
aken into account. Clinical manifestations of malignant insuli-
oma are similar to those of benign forms [10], but may be more
evere and prolonged due to the greater production of insulin and
roinsulin by the metastatic tumoral mass. Conversely, malig-
ant insulinoma may be first diagnosed as a non-functioning
ancreatic NET becoming secondarily functioning. The sever-
ty of hypoglycaemia thus varies from patient to patient and there
s no strict relationship with the tumor burden.
Time to diagnosis from first onset of neuroglycopenic or
drenergic symptoms is also variable, from 1 month to 17 years
17,20]. Synchronous metastasis appears to be the most frequent
resentation. Rarely, malignancy is diagnosed at the time of
ecurrence: according to Hirshberg, this is the case of 2% of
nsulinomas as a whole. The frequency of metachronic liver
etastasis in malignant insulinoma as reported by two teams
as respectively 8% and 11% [7,17], with an interval of 3 or 9
ears [8,17].
Although this has not been definitely demonstrated in insuli-
omas, relapse could be more frequent in insulinoma classified
s pancreatic tumor of uncertain prognosis according to the
004 WHO classification, for which prolonged surveillance is
herefore advisable [21].
.4.  Biological  markers
The diagnosis of organic hypoglycaemia is made on the
asis of clinical and biological criteria. Biological markers,
owever, have no demonstrated role in prognosis or follow-up.
xploration is conducted in the same way whether a benign or
alignant tumor is suspected. The criteria and thresholds for
iological diagnosis of inappropriate hypersecretion of insulin
≥ 3 mU/l) or of proinsulin (≥  5 pmol/l) with concurrent hypo-
lycaemia (≤  0.45 g/l) are similar [22]. However, insulinemia
nd C-peptide levels 2 to 3-fold higher in malignant forms,
nd 72h-fast test more rapidly proved positive were reported
alignant insulinoma [4,17].
Once symptoms have been brought under control, the use-
ulness of regular surveillance of glycaemia is debatable and
hould be reserved for periods of assessment or severe forms,
eing possibly anxiogenic for the patients and relatives.
Chromogranin A, which is elevated in 50% of cases, should
e measured, as in any pancreatic NET [17]. Other hormonal
ssays are to be considered on a case-to-case basis, according to
linical presentation [20].
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.5.  Genetics
More than 97% of malignant insulinomas are sporadic and
arely reveal any genetic predisposition syndrome. A few cases
ssociated with MEN-1 and 1 case associated with type-1
eurofibromatosis have been reported [23]. Systematic genetic
nalysis is thus not recommended. Relevant records on per-
onal or familial history compatible with a genetic predisposition
yndrome, clinical examination and calcium assessment are
ecommended. In MEN-1, there is no phenotype-genotype cor-
elation indicative of malignant insulinoma; there has, however,
een a report of three male members of an Iranian family bearing
 (c199 200del2) mutation who developed insulinoma that was
n two cases malignant [24]. In addition, malignant insulinoma
ay be multiple, with no demonstrable genetic syndrome [17].
.6.  Morphologic  and  functional  imaging
Morphologic and functional imaging is performed to specify
he staging and guide the indication of metabolic radiotherapy.
issemination is primarily intra-abdominal and locoregional,
ffecting the first lymph-node relays, adjacent tissue (adipose
issue and vessels) and peripancreatic organs (spleen, stomach,
iliary tract, liver, etc.) [25]. Liver metastasis is also frequent
20]. The classic subsequent extension of pancreatic NETs is
o the mediastinal nodes, neck and bone or, more rarely, the
ulmonary parenchyma [26]. A few cases of locally advanced
orms, known as “giant insulinoma”, have been reported [27].
Pretreatment assessment should include abdominopelvic CT
ith early liver arterial phase, possibly associated to hepatic MRI
o determine pancreatic and hepatic involvement. Endoscopic
ltrasound plays an important role in locating the insulinoma,
etermining the anatomic relation to the pancreatic ducts and
essels and exploring for multifocal involvement and lymph-
ode metastasis. If liver invasion is diffuse, thoracic CT or spinal
RI should also be performed.
Functional imaging by somatostatin receptor scintigraphy
OctreoScan®) is performed to localize the primary and look for
etastases. It is on average positive in 50% of cases [28–31].
ptake level should be qualified in view of possible metabolic
adiation therapy. Other markers for medical functional imaging
FDG, GLP1 or Gallium-labelled somatostatin analogues) have
een shown valuable [28,32–34].
In case of relapse, imaging assessment should look for multi-
ocal pancreatic lesions, lymph-node extension, liver metastases,
hich may be microscopic, best diagnosed by liver MRI or
elioscopy.
.  Prognosis
Pathologic classification in terms of well-differentiated tumor
r poorly-differentiated carcinoma is the first step of the
rognostic classification. In the vast majority of cases, malig-
ant insulinomas are well-differentiated, and presence of liver
etastasis is the major determinant of prognosis [17,35]. The
rognostic significance of lymph node metastasis is now well
stablished for pancreatic NET as a whole. At the metastaticinologie 74 (2013) 523–533 525
tage, initial assessment should specify tumor volume (notably
or liver metastases), progression on two successive mor-
hologic assessments, proliferation index and co-morbidity.
ncontrolled hypoglycaemia, liver tumor burden exceeding
0% of the liver volume, morphologic progression and Ki67
ndex greater than 10–20% are factors of poor prognosis.
In a epidemiological study, Lepage identified 81 cases of
alignant insulinoma in 30 European registries between 1985
nd 1994, with 5-year survival of 55.6% [36]. Survival as
eported in single-centre studies, was poorer: 16% 5-year sur-
ival in the Sao Paulo (Brazil) series with patients at advanced
tage (89% rate of liver metastasis) [4]; 29% 10-year survival in
he Mayo Clinic series of 13 cases over a period of 60 years [6];
edian survival of 19 months in relapsed patients in Danforth’s
eport of 17 personal cases seen between 1957 and 1982 at the
ational Institute of Health, Bethesda, analysed together with
5 cases from the literature (all stage IV) [18].
Causes of death have not been reported in all studies. When
nalysed, however, a wide range of causes were described
ncluding suicide, central catheter infection, pulmonary
mbolism, myocardial infarction associated with diabetes and
xcess weight, as well as tumor progression. Such causes of
eath highlight the need for multidisciplinary management, vig-
lance with respect to vascular and septic risk factors and psycho-
ogical follow-up. Respective mortality associated with hypo-
lycaemia or tumor progression is, at the present time, unknown.
.  Treatment
Treatment objectives are 2-fold: tumoral and hormonal
ecretion controls. In malignant insulinoma, the risk of hormone-
elated deaths or sequelae makes symptom control of major
mportance. At metastatic stage, all treatment options are
alliative. In the absence of randomised comparative stud-
es, prescription depends upon exact determination of the
isk/benefit ratio of each treatment modality. Expected efficacy
ith respect to hypoglycaemia is also taken into account but
arely reported. Individualising predictive factors and response
ubstitution markers is still in its preliminary steps.
.1.  Hormonal  secretion  control
Hormonal secretion control should be initiated within the first
onsultation. Given the gravity of hypoglycaemia, the treatment
bjective can only be complete symptomatic response. In case
f suspicion of residual hypoglycaemia, short hospital admis-
ions are advisable, to check that glycaemia is strictly normal.
ence, in the absence of data on long-term control of hypo-
lycaemia under purely symptomatic medical treatment, tumor
urden debulking should be systematically discussed.
Symptomatic treatment comprises:
 general measures:
◦ diet: fractionated feeding rich in slow sugars, advice on
use of slow and fast sugars to restore glycaemia in case of
malaise,
5 ndoc
•
4
t
m
I
b
f
T
h
l
4
4
i
r
S
i
i
i
r26 E. Baudin et al. / Annales d’E
◦ enteral nocturnal feeding if necessary, at home or in
repeated short-term hospital admission,
◦ central venous catheterisation (double in case of regular
glucose perfusion), to be envisaged according to severity
of hypoglycaemia, with strict respect of asepsis,
◦ identification or choice of a person of trust among the
patient’s family or friends, to be taught to recognise and
react to signs of hypoglycaemia,
◦  provision of telephone contact number where the care-team
can be reached at any time,
◦ initiation of early psychological support for patient and
family,
◦ driving to be avoided and possibly forbidden;
 medical antisecretion treatment:
◦ diazoxide 50–1500 mg/day is the usual first-line treatment
for symptomatic control. It controls insulin secretion by
opening potassium channels [37]. It is fast-acting but effec-
tive in only 50% of cases of insulinoma, and efficacy
in malignant insulinoma is unknown. However, symptom
control over periods of several years and even unexpected
development of diabetes has been reported. Side-effects
occur in 50% of cases: palpitation, nausea, anorexia, hir-
sutism, or sodium and water retention, which may be
improved by thiazide diuretics, which increase the effect
of diazoxide [38,39]. Progressive dosage is recommended,
beginning with low doses. When no efficacy is seen, dia-
zoxide should be discontinued, as there is no evidence that
combination of drugs improves the symptomatic control.
Certain authors have suggested that somatostatin analogues
may inhibit the hyperglycaemic effect of diazoxide,
◦ somatostatin analogues constitute an alternative to diazox-
ide in second line, and are well-tolerated and fast-acting.
Their action is based on SST2 and SST5 receptor expres-
sion controlling insulin secretion in the tumor. The dose
is 150–2000 g per day by subcutaneous injection, which
may be followed up by intramuscular injection of a slow-
release form (long-acting Sandostatin LP 20–30 mg or
Lanreotide 60–120 mg every 4 weeks) once efficacy has
been demonstrated [25,40]. An initial subcutaneous dose
delivered in hospital is advised, given reports of para-
doxical hypoglycaemia [38,41–43]. Although there are
several reports of long-term benefit in malignant insuli-
noma, the quality of the long-term symptomatic control
remains unclear [17,44,45]. When no efficacy is seen,
somatostatin analogues should be discontinued, as there is
no evidence of benefit in association with diazoxide. The
role of pasireotide in this indication is not known and para-
doxical hypoglycaemia could be even more frequent given
the higher inhibition of SST3 and SST5 receptors,
◦ there have recently been several reports of the interest
of everolimus in malignant insulinoma with intractable
hypoglycaemia [33,46–49]. These initial reports found that
everolimus gave remission of hypoglycaemia, allowing
glucose perfusion to be discontinued in several cases, or
termination of all other treatment for a period of months.
The effect can be rapid, within days [33]. A recent report
from the French Groupe d’Étude des Tumeurs Endocrines
s
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confirmed this benefit since a control of hypoglycemia was
found in 11 out of 12 patients with no recurrence [49].
Everolimus is an inhibitor of the Pi3K/AKT/mTOR path-
way, which is abnormally activated in NETs. Recently
published results from several phase-II and one phase-III
trial demonstrated an antitumoral effect of everolimus in
pancreatic NET. Hyperglycaemia and also hypertriglyc-
eridaemia are side-effects of everolimus exploited for
insulinoma treatment. Inhibition by everolimus of the
AMP/Jun/Fos pathway may lower insulin secretion, but can
also cause insulin resistance [50]. A fall in beta-cell count
under everolimus is another possible mechanism of hyper-
glycaemia [50]. Main side-effects are aphthae, fatigue,
diarrhoea, hypophosphoraemia and interstitial pneumopa-
thy, requiring tailored follow-up [51]. Given its toxicity,
everolimus is to be placed in third line for symptom control
after failure and/or intolerance to diazoxide and somato-
statin analogues,
◦ other treatments: oral corticosteroids (prednisone, dexa-
methasone) have been used on an occasional basis, with
ambivalent results, after failure of the above treatments
[52]. Their rapid action gives them a role in symptom
control; side-effects (including immunosuppression and
heightened risk of sepsis), however, require alternatives to
be found. It should be recalled also that chronic steroid
therapy is a contraindication to everolimus therapy in
the RADIANT trials suggesting that such combination
should be avoided [53]. Use of beta-blockers, phenytoin
(Dihydan®) and also calcium inhibitors and interferon in
malignant insulinoma was reported in the past [54–56],
although without proof of real and sufficient efficacy.
.2.  Antitumoral  treatment
Antitumoral treatment combines general and/or locoregional
herapy. The advent of metabolic radiation therapy and targeted
olecular therapy has increased the range of treatment options.
f symptomatic control is incomplete, in case of large tumor
urden, tumor progression or exceptional poorly differentiated
orms, antitumoral treatment should be performed urgently.
he benefit of the various antitumor options when addressing
ypoglycaemia control has been poorly described in the
iterature.
.2.1. Locoregional  antitumor  treatment
.2.1.1.  Surgery.  In malignant insulinoma, surgery is indicated
n well-differentiated locally advanced or metastatic forms; it
equires an experienced surgeon and anaesthesiologist [57,58].
urgery is the only potentially curative treatment in malignant
nsulinoma diagnosed at a locally advanced stage. It may be
ndicated as first-line treatment or, after objective response to an
nitial antitumoral treatment. Surgery should attempt a complete
esection of all macroscopic lesions. Mesenteric artery inva-
ion is a contraindication to surgery. At the metastatic stage
59–61], palliative liver surgery is classically of interest when
ore than 90–95% of the macroscopic tumor mass can be
emoved and/or symptom control is deficient. In addition, the
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umor burden should be slowly progressive and the Ki67 prefer-
bly below 10% [62,63]. In certain cases, given the potential
ravity of hypoglycaemia, less ambitious surgery is undertaken,
esecting 60–70% of the liver metastases. The benefit, however,
emains undetermined. Surgical mortality should not exceed 5%
ven at the metastatic stage. Five-year survival in most series
f selected well-differentiated NET exceeds 70% but specific
esults in malignant insulinoma patients were not mentioned.
elapse after surgery is 75% by 10 years, which highlights the
act that resection is never microscopically total, as was recently
emonstrated [64]. Abdominal lymph-node, peritoneal and or
sseous metastasis may also be considered for surgical resection
n a case by case basis. Surgical strategies are thus widely used in
alignant insulinoma [4,7,17]. Like in other well-differentiated
ET, survival benefit is not known and the contribution to
ymptom control has been little described [5,8,20]. Given the
mmediate impact on symptom control and the possibility of
acroscopically complete resection, surgery should be system-
tically discussed as a first-line line antitumor option. American
uidelines consider liver transplant in young patients without
ontrolled secretion and with exclusive hepatic extension [3].
ive-year survivorship after transplantation in the absence of
isk factors is 66% [62,63].
.2.1.2. Hepatic  chemoembolisation.  Transarterial liver
mbolisation (TACE) is frequently used in metastatic malignant
nsulinoma, being easily accessible in practice and one of
he few options which has been shown to produce a quick-
cting on secretion [4,30,46]. There are several reports of
ongstanding symptom control [30,65–67]. TACE is applied
n well-differentiated NET that is inoperable, incompletely
esected or evolutive [68,69]. In French, American and
uropean guidelines, it is recommended as a second-line
ocoregional option after surgery [19,33,70]. Various tech-
iques are available, and the choice of the technique is presently
overned by practical availability, feasibility based on tumor
resentation and by contraindications. Published series for
ell-differentiated NET report tumoral response in 30–70%
f cases, the best response being especially observed when
nvolvement of the hepatic parenchyma is less than 30%,
etastases are vascularised and/or the metastases treated are
ess than 3–5 cm in size [68]. Two treatment sessions are
ften performed, with subsequent sessions depending on the
uality of symptomatic and tumoral response. When TACE
eeds to be repeated frequently, association to or, a systemic
reatment may be considered. The associated morbidity and
ortality is increase in case of large tumors and systemic
reatment should be considered as an alternative in such
ases.
.2.1.3. Hepatic  radiofrequency  ablation  or  cryoablation.
epatic radiofrequency ablation is currently used to treat small
etastases of well-differentiated NET [71]. It was only recentlyntroduced, and may be performed percutaneously or comple-
entarily to liver surgery, destroying metastases inaccessible to
urgery. French and European guidelines place the technique as
 second-line locoregional option when surgery is not feasible
4
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19,70]. Nevertheless, in the case of insulinoma, radiofrequency
blation, having low associated morbidity, may be an interest-
ng alternative to surgery for small tumors or patients with high
urgical risk, or in case of uncertain short-term prognosis. There
ave been a few reports of symptomatic benefit in malignant
nsulinoma [17,20]. Metastasis size, ideally less than 3 cm, is
he main predictive factor for response to radiofrequencies. The
echnique is also used to treat pulmonary nodules and, more
ecently, bone metastases. Mortality is low, at less than 1%.
lternatives such as microwave ablation are under assessment.
ryotherapy may be associated to liver surgery, to spare the
arenchyma in case of multiple small lesions.
.2.1.4. External  radiation  therapy.  External radiation therapy
s indicated for painful or unstable secondary bone lesions, cuta-
eous and cerebral metastatic locations [72]. The benefit in
ell-differentiated tumors has not been well studied: stabilisa-
ion is the most frequent short-term response. The role of external
adiation therapy in controlling primary tumors, and pancreatic
umors in particular, at the metastatic stage has not been deter-
ined. The development of stereotactic surgery broadens the
ange of indications for external radiation therapy, positioning
t as a new alternative to locoregional techniques as a whole in
ocalised tumor.
.2.2. Systemic  treatments
Systemic treatments are discussed in patients who remain
ymptomatic despite the above-mentioned treatments or whose
umor is considered aggressive like patients with greater than
0% tumor progression per year according to the RECIST crite-
ia, large tumor volume (> 30% liver invasion, bone metastasis),
i67 index greater than 10% or with an exceptional poorly dif-
erentiated tumor type [13,73]. Systemic treatment should also
e considered whenever locoregional treatments need to be fre-
uently repeated (at less than 6 months’ interval). Pancreatic
ETs are relatively chemo-sensitive and recent phase-III tri-
ls with everolimus and sunitinib have demonstrated benefit in
rogression-free survival. The rarity of randomised studies and
he lack of predictive factors for tumoral response make the
est sequence uncertain. At all events, systemic treatment pre-
upposes rigorous assessment of the clinical and morphological
argets, repeated at least every 3 months.
.2.2.1. Poorly  differentiated  malignant  insulinoma.  This sub-
roup was recently renamed G3-neuroendocrine carcinoma in
he recent 2010 WHO classification. It has not been definitely
roved that malignant insulinoma can present as poorly differ-
ntiated, although some reports of unusually aggressive forms
aise the question [14–16]. It is therefore important to state that
he reference chemotherapy for poorly differentiated neuroen-
ocrine carcinoma is an association of etoposide and cisplatin
74–76]..2.2.2. Well-differentiated  malignant  insulinoma.  This sub-
roup was renamed G1 or G2-NET in the recent 2010 WHO
lassification. Optimal treatment sequence remains to be deter-
ined. Chemotherapy and metabolic radiation therapy, however,
5 ndoc
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ore frequently ensure objective response and should be con-
idered as first-line systemic treatments whenever a reduction in
umor volume is sought.
4.2.2.2.1.  Somatostatin  analogues.  The antitumoral action
f somatostatin analogues has not been thoroughly assessed in
alignant insulinoma, and precise guidelines for use cannot be
aid down. Their symptomatic benefit, tolerance and simplicity,
owever, make them an attractive option, and it is noteworthy
hat tumor stabilisation was achieved in 18–57% of cases for a
edian 18 months in several reports that include primary pancre-
tic NET [77–84]. This was confirmed in a recent report from the
erman network concerning mainly grade-1 ileal tumor of small
etastatic volume, in which time to progression was increased
y Sandostatin® LAR. Thus, long-acting somatostatin ana-
ogues are an option in small-volume, slowly progressive and/or
ow-grade malignant insulinoma. Again, absence of paradoxi-
al hypoglycaemia should be first evaluated by subcutaneous
njection.
4.2.2.2.2. Chemotherapy  in  well-differentiated  pancreatic
alignant insulinoma  (G1-G2  NET).  Chemotherapy plays
n important role in well-differentiated pancreatic NETs in
eneral and, by extension, in malignant insulinoma. Reports,
owever, have not specified symptomatic benefit in terms of
ypoglycaemia control [4,5]. French and European guidelines
ecommend chemotherapy in first line for pancreatic tumor
f poor prognosis [2,70]. European and American guidelines
uggest everolimus as an alternative in case of malignant isnuli-
omas [2,3].
For monochemotherapy, several older series reported anti-
umor efficacy for 5 fluorouracil, doxorubicin, streptozotocin
nd dacarbazine [85–87]. More recently, antitumor efficacy
as reported for temozolomide, with 8% or 34% objective
esponse in two retrospective series of 12 and 53 patients,
espectively [88,89]. In 1992, Moertel established the first ref-
rence chemotherapy regimen, demonstrating survival benefit
ith an association of adriamycin and streptozotocin com-
ared to 5-fluorouracil-streptozotocin or chlorozotocin [90,91]
his trial has not been replicated yet. The initially reported
bjective response rate of 69% has been brought down to
–40%, without complete response, in more recent series
90,92–94]. In 5–10% of cases, surgery can be considered
fter a response has been obtained. Median response duration
s 9–19 months. Alternative regimens are under development.
ndeed, two studies suggested the interest of associating 5-
uorouracil to oxaliplatin or gemcitabine to oxaliplatin, with
7% and 40% objective response in 11 and five patients, respec-
ively. Finally, a recent phase-II trial reported 70% objective
esponse with an association of capecitabine-temodal as first-
ine treatment for well-differentiated pancreatic NETs [95].
hus, at present, three chemotherapy regimens have shown
igns of antitumor efficacy, but comparative studies are lack-
ng. Their toxicity profiles and the individual comorbidities are
hus the key elements in the therapeutic choice. The guidelines
ecommend the combination of streptozotocin to doxorubicin
nd 5-fluorouracil in first line, since more data are available for
hese associations. Cardiologic and nephrologic surveillance is
ecommended.
r
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4.2.2.2.3.  Peptide  receptor  radionucleide  therapy  (PRRT).
RRT uses somatostatin analogues, labelled with radionuclei-
es, which internalised within neuroendocrine cells after their
inding to the somatostatin receptors. European guidelines
ecommend the use of octreotide or octreotate labelled with
ttrium or lutetium [96]. Being poorly accessible, this treat-
ent is recommended in all guidelines as a second-line option
or aggressive forms. Nevertheless, metabolic radiation ther-
py is an alternative to chemotherapy, to be considered in
ase of elevated uptake at the somatostatin receptor scintig-
aphy. [90Y-DOTA0,Tyr3] octreotide achieves some complete
umoral responses (2–5%) and a partial objective response
ate varying from 7 to 22% for mean cumulative activity per
atient of 5–13 GBq [97–104]. These studies also reported clin-
cal improvement in 34–100% of cases [98,100,104,105]. The
rst, recently published, phase-II multicentre study in refrac-
ory carcinoma reported 4% objective response and a median
rogression-free survival of 16 months [106]; symptomatic con-
rol was achieved in 50% of cases for a median duration of 3
onths. [177Lu-DOTA0,Tyr3] octreotate seems to be the most
nteresting radiolabelled peptide in terms of receptor affinity and
nternalisation [107]: Kwekkeboom et al. reported 2% complete
nd 26% partial objective morphologic response in 131 patients
reated with cumulative activity ranging from 22.2 to 29.6 GBq
108]. Predictive factors for response to treatment were strong
ptake at the diagnostic scintigraphy and small liver metastasis
olume. The same team demonstrated a positive impact on qual-
ty of life in a series of 50 patients, with improvement in fatigue,
nsomnia and pain scores [109]. The main side-effects were
emotoxicity, fatigue, and digestive disorder (nausea, vomiting,
norexia) [110]. Long-term severe impairment of renal function
nd myelodysplasia has been reported. Age exceeding 70 years,
one metastasis, history of chemotherapy and creatinine clear-
nce less than 60 ml/min are factors for higher toxicity [111],
n which case alternative treatment should be considered. Of
ote, rapid symptomatic response has been reported in several
ases of patients with malignant insulinoma treated by metabolic
adiation therapy [47,112,113].
4.2.2.2.4. mTOR  pathway  inhibitors.  The first phase-II
tudy demonstrated 7% objective response in 15 progressive
ancreatic NET treated with temsirolimus [114]. Subsequently,
% objective response and progression-free survival of 9.7
onths were reported in a stratified phase-II study of everolimus
n 115 patients with pancreatic NET [53]. Finally, two stud-
es combining everolimus with octreotide reported respectively
7% and 4% objective response in 30 and 45 progressive or non-
rogressive pancreatic NETs, with progression-free survival of
6 months [53,115]. A recent randomised double-blind phase-III
tudy of everolimus versus placebo in well-differentiated pro-
ressive pancreatic NET demonstrated a significant benefit in
rogression-free survival in the everolimus arm (11.4 months
ersus 4.6 months with placebo) [116]. Objective response
as obtained in less than 5% in the everolimus arm, and noeceived European market authorisation for the treatment inop-
rable progressive well-differentiated pancreatic NET. Although
ecommended as second line for well-differentiated pancreatic
ndocr
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ET therapy in French and European guidelines, everolimus
s recommended as an alternative first-line therapy in the spe-
ific case of malignant insulinoma. Indeed, the combinations of
ts hyperglycaemic and antitumoral effect make everolimus an
deal therapy especially in the case of tumors presenting with
symptomatic low tumor burden.
4.2.2.2.5. Antiangiogenic  treatments.  Objective response
ates of 16%, 19% and 11% were successively reported in
hase-II studies of sunitinib, pazopanib and sorafenib in pancre-
tic NET, with 70%, 81% and 61% 6-months progression-free
urvival, indicating antitumoral efficacy [117–119]. A recent
andomised double-blind phase-III study of sunitinib ver-
us placebo in well-differentiated progressive pancreatic NET
howed significant clinical benefit in terms of progression-free
urvival in the sunitinib arm (11.4 months, versus 5.5 months
ith placebo) [120], with a 9% objective response rate. Ini-
ial claims of benefit in overall survival were not confirmed on
ater analysis. This treatment recently received French market
uthorisation for the treatment of inoperable progressive well-
ifferentiated pancreatic NET. However, a risk of onset of severe
ypoglycaemia has since been reported with sunitinib [121,122].
herefore, the use of sunitinib in the setting of malignant insuli-
oma requires additional investigations before this agent can
e considered as an option [122]. Studies of combinations of
ntiangiogenic agents and chemotherapy are presently under-
ay [123,124].
4.2.2.2.6.  Trials.  Due to their uncertain behaviour, patients
ith malignant insulinomas are only rarely enrolled in trials.
pecific trials should be envisaged..  Follow-up
In benign insulinoma, no surveillance is indicated.
•
•
Objecve:  resoluo n of hyp oglycaemia = C
1. DIAZOXIDE
YES
Discuss tumour deb ulki ng
YES
Discuss tumour deb ulki ng
YES
Discuss tumour deb ulki ng
NO or IN TOL E
2. SOMASTOS
NO or IN TOL E
3. EV EROLIMU
NO or INTOLE
4. Other  an-t
Urgent aco ns  coup led  to medi cal t reatment 
Fraconated enriche d meal or enteral feeding
Glucos e perf usio n, 1–2 centr al lin es
Specialist nu rses,  die cian
Idenfy and  educate family  physician  and  family
Control anxiet y: pa ent,  famil y,  car e team
sCR ?
sCR ?
sCR ?
Fig. 1. Symptomatic treatment inologie 74 (2013) 523–533 529
In insulinoma of uncertain prognosis, although the interest of
urveillance is unproven, two assessments (clinical examination
nd abdominal MRI) are recommended every 6 months to 2 years
or the first 10 years and then every 2 to 5 years all lifelong. This
trategy should be reviewed as soon as a sufficient cohort of
atients under prolonged follow-up is reached. Such follow-up
as to be proposed also in case of incomplete R1 resection.
In malignant insulinoma, surveillance should be adapted in
he light of symptom control and tumoral prognosis. Follow-
ng resolution of hypoglycaemia, clinical and morphological
ssessments should be made at 3 months and repeated every
 months in case of stability. The role of glycaemia monitoring
s controversial.
The nutritional status, the psychological impact on patient
nd family, the strict rules of asepsia when dealing with central
atheter should be assessed in parallel with symptomatic and
umoral control and monitoring of treatment tolerance.
Future studies should seek to determine the quality (efficacy,
uration) of symptom control in parallel with assessment of
umor response.
.  French  guidelines  for  the  management  of  malignant
nsulinoma
The guidelines are as follows (Figs. 1 and 2):
 complete and lasting control of symptoms is the prime thera-
peutic objective; diazoxide or somatostatin analogues are the first-line treat-
ment options for the control of hypoglycaemia;
 everolimus is recommended as a second or third-line in case
of intolerance or progressive failure of control on diazoxide
ompl ete  Sym ptom ac  Repo nse (sCR )
RANCE
TA TIN ANALOGUES
RANCE
S an d/or LIVER CHE MOEMBOLISATION
RANCE
umoural opons   to reduce  se creon  volume 
of malignant insulinoma.
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Stable  disease , Grade G1
Low to  mode rate tumour volume
Evoluve  disease , Grade G1 -G2
Low tumour volume
Evolu ve disease
Large  tumour volume
Surgery
Locoregional opons
1st li ne: SMS analogues 
if slowly progressive
Alternave : Everolimus if rapidly
progressive
1st line: Systemic chemotherapy
if rapidly progressive
Alter nave : PR RT if sl owly progressive
2nd line:   Everolimus
Alternave : PRRT or chemotherapy
3rd line: PR RT
Alter nave :  everolimus or ch emotherapy
2nd line:   Everolimus
lume 
•
•
•
D
c
RFig. 2. Tumour vo
or somatostatin analogues therapy, especially in case of low
tumor burden;
 liver chemoembolisation can be an emergency treatment for
severe hypoglycaemia resistant to medical management given
its antisecretory action especially in case of poor prognostic
outcome;
 surgery is indicated when macroscopically complete resection
of primary and metastases is feasible with low risk (< 3–5%)
of morbidity or mortality. At least two morphological assess-
ments should be made to check tumor slow progression. Other
locoregional techniques as a whole are alternative treatments;
 other antitumoral options are to be considered loss when func-
tional control is lost or in case of tumor of poor prognosis:
◦ in operable stable or weakly progressive well-differentiated
tumors with medically controlled symptomatology, macro-
scopic tumor reduction should be considered, using
low-morbidity techniques,
◦  in inoperable symptomatic tumor resistant to medical or
locoregional treatments or in case of large liver tumor
volume or progressive tumor, the medical options are
metabolic radiation therapy, systemic chemotherapy and
everolimus. Everolimus is indicated for persistent hypogly-
caemia. Chemotherapy is to be considered in case of large
tumor volume and/or rapidly progressive tumor. Metabolic
radiation therapy depends on access to an equipped cen-
tre and on scintigraphic somatostatin receptor uptake.
Metabolic radiation therapy is to be considered in case of
large tumor volume and/or slowly progressive tumor.
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